Sun Pharma MD Dilip Shanghvi says in Q2, Sun Pharma recorded double-digit topline growth and strong margins, driven by market share gain in India, and sustained ramp-up of global specialty biz.
It seems the previous capital raised by Suzlon has been blown away and the company is going back to its existing shareholders for raising fresh capital worth ₹1,200 crore through a rights issue.
Cyrus Soli Poonawalla’s Serum Institute of India made the most of the country’s demand for vaccines.
Acquisitions and product focus make Shanghvi India's wealthiest drug maker.
The company, set up and funded by Sun Pharma founder and MD Dilip Shanghvi’s family office, is focusing on AI-led pharma research and development, even offering tech tools to the industry for R&D.
US sales have dropped to less than a third of overall revenue from nearly half five years ago and profits have taken a beating despite cost synergies after the acquisition of Ranbaxy Laboratories.
